Welcome to our dedicated page for Novo-Nordisk A S SEC filings (Ticker: NONOF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for NOVO NORDISK A/S B NEW (NONOF) provides access to disclosures filed by Novo Nordisk A/S as a foreign issuer. These filings give detailed insight into the company that underlies NONOF, including its therapeutic focus, clinical programmes, governance decisions and insider transactions.
Through Form 6-K and other submissions, Novo Nordisk reports material developments such as FDA approval of the Wegovy pill, a once-daily oral semaglutide 25 mg tablet for weight management and reduction of major adverse cardiovascular events in adults with obesity or overweight and specific cardiovascular conditions. Filings also describe the OASIS phase 3 programme in obesity, phase 2 results for amycretin in type 2 diabetes, and outcomes of the evoke and evoke+ phase 3 trials in Alzheimer’s disease.
Regulatory documents further cover corporate matters. Extraordinary general meeting resolutions detail changes in the Board of Directors and the composition of committees like the Audit, Remuneration, People and Governance, and Research & Development Committees. Separate filings disclose trading in Novo Nordisk shares by board members, executives and associated persons, in line with market abuse rules, providing transparency around insider activity in Novo Nordisk B shares listed on Nasdaq Copenhagen and ADRs listed on the New York Stock Exchange.
On Stock Titan, these SEC filings are updated from EDGAR and can be paired with AI-powered summaries that explain the key points in plain language. Users researching NONOF can use this page to quickly understand what Novo Nordisk reports in its official documents, from clinical data and product approvals to governance changes and insider transactions, without reading every page of each filing.
Novo Nordisk A/S will convene an Extraordinary General Meeting to elect new members of the Board of Directors on 14 November 2025. The decision follows dialogue with the Novo Nordisk Foundation about board composition; the Foundation holds the majority of votes. The Board concluded that electing new members via an EGM is in the best interest of the company and shareholders to provide clarity on future governance.
Chair Helge Lund, Vice Chair Henrik Poulsen, and independent directors Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law and Martin Mackay will not stand for election at the EGM. Kasim Kutay (not independent) and employee‑elected members Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen and Thomas Rantzau will remain on the Board.
Novo Nordisk will host an investor conference call at 15:00 CEST on 21 October 2025, with a dial‑in link available on the company’s investor website.
Novo Nordisk will acquire Akero Therapeutics for $54 per share in cash, representing total consideration of about $4.7B, plus a contingent value right of $6 per share (about $0.5B) on closing. The deal adds Akero's FGF21 analogue efruxifermin (EFX), described as the only therapy to show significant fibrosis regression in phase 2 patients with compensated cirrhosis (F4).
EFX is positioned to treat metabolic dysfunction-associated steatohepatitis (MASH), a comorbidity closely linked to diabetes and obesity; the filing notes >40% of MASH patients have type 2 diabetes and >80% are overweight or living with obesity. Novo Nordisk highlights ongoing programs including SYNCHRONY Histology, SYNCHRONY Outcomes, and SYNCHRONY Real-World to evaluate EFX across F1–F4 disease stages, with once-weekly subcutaneous dosing reported as generally well tolerated in trials to date.